Leerink Partners analyst Thomas Smith reiterated a Buy rating on Dice Therapeutics (DICE – Research Report) yesterday and set a price target of $46.00. The company’s shares closed last Thursday at $20.05.
According to TipRanks.com, Smith is ranked 0 out of 5 stars with an average return of -30.7% and a 10.8% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Eledon Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dice Therapeutics with a $50.50 average price target.
Based on Dice Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.2 million. In comparison, last year the company earned revenue of $225K and had a GAAP net loss of $6.02 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Read More on DICE:
- Robert W. Baird Keeps a Hold Rating on Vir Biotechnology (VIR)
- Robert W. Baird Reaffirms Their Buy Rating on Pinterest (PINS)
- Leerink Partners Reaffirms Their Buy Rating on Solid Biosciences (SLDB)
- Robert W. Baird Sticks to Its Buy Rating for Paypal Holdings (PYPL)
- Viking Therapeutics (VKTX) Initiated with a Buy at Leerink Partners